Free Trial
→ An $8 trillion-dollar discovery 17,000 ft underwater (From Porter & Company) (Ad)tc pixel

Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% - Still a Buy?

Written by MarketBeat
October 21, 2025
Cardiol Therapeutics logo with Medical background

Key Points

  • Cardiol Therapeutics Inc. shares increased by 6.7% during mid-day trading, reaching C$1.60, with a significant trading volume of 365,254 shares.
  • The company has a market capitalization of C$143.18 million and is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRxTM.
  • Cardiol Therapeutics has a negative price-to-earnings ratio of -3.56, indicating a potential risk, yet it maintains a healthy current ratio of 2.49 and a quick ratio of 6.84.
  • Interested in Cardiol Therapeutics? Here are five stocks we like better.

Shares of Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) shot up 6.7% during mid-day trading on Tuesday . The stock traded as high as C$1.63 and last traded at C$1.60. 365,254 shares traded hands during mid-day trading, an increase of 251% from the average session volume of 104,049 shares. The stock had previously closed at C$1.50.

Cardiol Therapeutics Trading Up 14.0%

The firm has a market capitalization of C$143.18 million, a price-to-earnings ratio of -3.56 and a beta of 0.86. The company has a fifty day moving average price of C$1.53 and a two-hundred day moving average price of C$1.63. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cardiol Therapeutics Right Now?

Before you consider Cardiol Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.

While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.